Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sayed Hashemi"'
Autor:
Chris Dickhoff, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, David J. Heineman, Teodora Radonic, Peter M. van de Ven, Imke H. Bartelink, Lilian J. Meijboom, Juan J. Garcia-Vallejo, Daniela E. Oprea-Lager, Tanja D. de Gruijl, Idris Bahce
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected
Externí odkaz:
https://doaj.org/article/b810006f73e5465ca6860f5c7acd4a6c
Autor:
Fariba Tohidinezhad, Dennis Bontempi, Zhen Zhang, Anne-Marie Dingemans, Joachim Aerts, Gerben Bootsma, Johan Vansteenkiste, Sayed Hashemi, Egbert Smit, Hester Gietema, Hugo JWL. Aerts, Andre Dekker, Lizza E.L. Hendriks, Alberto Traverso, Dirk De Ruysscher
Publikováno v:
European Journal of Cancer, 183, 142-151. Elsevier Ltd.
European Journal of Cancer, 183, 142-151. ELSEVIER SCI LTD
Tohidinezhad, F, Bontempi, D, Zhang, Z, Dingemans, A-M, Aerts, J, Bootsma, G, Vansteenkiste, J, Hashemi, S, Smit, E, Gietema, H, Aerts, H J WL, Dekker, A, Hendriks, L E L, Traverso, A & de Ruysscher, D 2023, ' Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors ', European Journal of Cancer, vol. 183, pp. 142-151 . https://doi.org/10.1016/j.ejca.2023.01.027
European Journal of Cancer, 183, 142-151. Pergamon
European Journal of Cancer, 183, 142-151. ELSEVIER SCI LTD
Tohidinezhad, F, Bontempi, D, Zhang, Z, Dingemans, A-M, Aerts, J, Bootsma, G, Vansteenkiste, J, Hashemi, S, Smit, E, Gietema, H, Aerts, H J WL, Dekker, A, Hendriks, L E L, Traverso, A & de Ruysscher, D 2023, ' Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors ', European Journal of Cancer, vol. 183, pp. 142-151 . https://doi.org/10.1016/j.ejca.2023.01.027
European Journal of Cancer, 183, 142-151. Pergamon
Introduction: Immunotherapy-induced pneumonitis (IIP) is a serious side-effect which requires accurate diagnosis and management with high-dose corticosteroids. The differ-ential diagnosis between IIP and other types of pneumonitis (OTP) remains chall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4323d7bfdd7d4fc3c08583aaf0494b2
https://pure.eur.nl/en/publications/18c8f75f-c320-414f-920e-fb54ae6bd1aa
https://pure.eur.nl/en/publications/18c8f75f-c320-414f-920e-fb54ae6bd1aa
Autor:
R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho
Publikováno v:
ANNALS OF ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffaf9a40fb0dc0e69e9a2d49edf76954
https://doi.org/10.1016/j.annonc.2021.11.010
https://doi.org/10.1016/j.annonc.2021.11.010
Autor:
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, Lynette M. Sholl, Weiwei Shi, Joao V. Alessi, Alessio Cortellini, Claudia A. M. Fulgenzi, Patrizia Viola, David J. Pinato, Sayed Hashemi, Idris Bahce, Ilias Houda, Ezgi B. Ulas, Teodora Radonic, Juha P. Väyrynen, Elin Richardsen, Simin Jamaly, Sigve Andersen, Tom Donnem, Mark M. Awad, David J. Kwiatkowski
Publikováno v:
JAMA Oncology, 9(1), 51-60. American Medical Association
Rakaee, M, Adib, E, Ricciuti, B, Sholl, L M, Shi, W, Alessi, J V, Cortellini, A, Fulgenzi, C A M, Viola, P, Pinato, D J, Hashemi, S, Bahce, I, Houda, I, Ulas, E B, Radonic, T, V?yrynen, J P, Richardsen, E, Jamaly, S, Andersen, S, Donnem, T, Awad, M M & Kwiatkowski, D J 2023, ' Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC ', JAMA Oncology, vol. 9, no. 1, pp. 51-60 . https://doi.org/10.1001/jamaoncol.2022.4933
Rakaee, M, Adib, E, Ricciuti, B, Sholl, L M, Shi, W, Alessi, J V, Cortellini, A, Fulgenzi, C A M, Viola, P, Pinato, D J, Hashemi, S, Bahce, I, Houda, I, Ulas, E B, Radonic, T, V?yrynen, J P, Richardsen, E, Jamaly, S, Andersen, S, Donnem, T, Awad, M M & Kwiatkowski, D J 2023, ' Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC ', JAMA Oncology, vol. 9, no. 1, pp. 51-60 . https://doi.org/10.1001/jamaoncol.2022.4933
ImportanceCurrently, predictive biomarkers for response to immune checkpoint inhibitor (ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine patient selection and guide precision therapy.ObjectiveTo develop a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6d0febc37ee77d1b041f50df5fcc11
https://research.vumc.nl/en/publications/bf87beb5-16ad-466d-9519-a7e96a470fe3
https://research.vumc.nl/en/publications/bf87beb5-16ad-466d-9519-a7e96a470fe3
Publikováno v:
Cement Wapno Beton. 26:218-232
Two families of heavy concrete were investigated in this project, the first containing hematite and the second magnetite aggregates. Boron carbide also replaced cement in mass of 2.5, 5 and 10%. Once again, in these compounds the content of cement wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a36289d76dff9970baf5e382cb8ffcbd
https://doi.org/10.32047/cwb.2021.26.3.4
https://doi.org/10.32047/cwb.2021.26.3.4
Ergebnisvergleich nach Kurzschaft-H��ftendoprothesen zwischen ���jungen��� und ���alten��� Patienten
Autor:
Sayed Hashemi, Omolbanin
Kurzschaftprothesen sind heute weit verbreitet und f��r j��ngere Patienten beliebt, da sie durch kleinere Zug��nge implantiert und im Bedarfsfall auch gegen ein Standard-Implantat ausgetauscht werden k��nnen. Der in dieser Untersuchun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5a7fb2e996817508543b88ef5814bd